| abstract |
Disclosed is the use of agents and compositions that selectively inhibit the alternative complement pathway to inhibit or treat physiological damage resulting from traumatic brain injury (TBI), spinal cord injury (SCI) or related conditions. Is done. Preferred reagents used to suppress damage due to TBI or SCI include those that inhibit factor B, and anti-factor B antibodies represent particularly preferred agents. |